Clinical significance of tumor interstitial T lymphocyte subset activity in non-small-cell lung cancer.
- Author:
Lei XUE
1
;
Ju CHEN
;
Jiang-zhou PENG
;
Bai-shen CHEN
;
Ping HUA
;
Yan-qi YANG
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Carcinoma, Non-Small-Cell Lung; immunology; pathology; Female; Humans; Lung; immunology; Lung Neoplasms; immunology; pathology; Male; Middle Aged; Neoplasm Staging; T-Lymphocyte Subsets; immunology; T-Lymphocytes, Regulatory; immunology
- From: Journal of Southern Medical University 2009;29(12):2456-2458
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the relation of tumor interstitial T lymphocyte subset activity to the clinical staging of non-small-cell lung cancer (NSCLC) and the immune response.
METHODSImmunohistochemical staining for CD4(+), CD8(+) and CD4(+)CD25(+) Foxp3(+) (regulatory T cells, Treg) T cells was performed on paraffin-embedded tissues from 60 NSCLC cases.
RESULTSCompared to stage I/II NSCLC patients, patients in stage III/IV showed a significant decrease in the percentage of CD4(+) and CD4(+)/CD8(+) T cells (P<0.05) and an increase in CD8(+) and CD4(+)CD25(+) Foxp3(+) T cells (P<0.05). Treg cells were enriched in the tumor tissue as compared with those in the adjacent tissues.
CONCLUSIONSThe proportion of CD4(+)CD25(+) Foxp3(+) Treg cells is positively correlated to the clinical staging of NSCLC, in which T cell-mediated immune response is suppressed.
